RxDoctor Payments Data

Maria Jaurrieta

Nurse Practitioner · Miami, FLNPI 1457704645

Payments from drug & device makers

$3,065in general payments, 2019–2025

Across 56 payments — averaging $54.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Stemline Therapeutics Inc.$685
  • Merck$208
  • Novartis$178
  • Johnson & Johnson$176
  • Daiichi Sankyo Inc.$156
  • plus $523 from 8 others

What the payments were for

  • Consulting fees$1,36044%
  • Food & beverage$1,70556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,065 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$8,547
Medicare patients
24
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib26$402,045
NerlynxNeratinib Maleate13$257,427
EliquisApixaban13$7,687
Exemestane43$7,543
Enoxaparin Sodium12$3,406
Anastrozole137$2,332
Letrozole49$1,602
Ibandronate Sodium40$1,043
Tamoxifen Citrate21$592
Lidocaine-PrilocaineLidocaine/Prilocaine14$161
Ondansetron Hcl11$142
Alendronate Sodium13$127
Gabapentin18$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$142$409,73239 claims
Puma Biotechnology, Inc.Nerlynx$34$257,42713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →